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Abstract
Background: Cocoa, mixed with other food ingredients, intake can have beneficial effects on cardiovascular disease (CVD)
biomarkers. We compared the effects of 4 cocoa cream products on some of these biomarkers.
Methods and Findings: In this multi-centered, randomized, controlled, double-blind, parallel trial, volunteers (n=113; age
range: 43–65 years) who were pre-hypertensive, stage-1 hypertensive and hypercholesterolemic received one of 4 cocoa
cream products (13 g/unit; 1 g cocoa/unit, 6 units/d; 465 Kcal/d) added to a low saturated fat diet for 4 weeks. The groups
were: A) (n=28), cocoa cream considered as control; B) (n=28), cocoa+hazelnut cream (30 g/d hazelnuts); C) (n=30),
cocoa+hazelnuts+phytosterols (2 g/d); and D) (n=27), cocoa+hazelnuts+phytosterols+soluble fiber (20 g/d) the patented
‘‘LMN product’’. Primary outcome measures were BP, LDL-c, apolipoprotein B-100 (Apo B), ApoB/ApoA ratio, oxidized LDL
(oxLDL) and high-sensitive C-reactive protein (hsCRP) determined at baseline and post-cocoa cream product intake.
Statistical analysis used was ANCOVA or mixed models (in case of repeated measurements), with baseline observation
included as a covariate. After 4 weeks, compared to product A, product C reduced LDL-c by 11.2%, Apo B by 8.1% and
ApoB/ApoA ratio by 7.8% (P=0.01). LMN decreased LDL-c by 9.2%, Apo B-100 by 8.5%, ApoB/ApoA ratio by 10.5%, hsCRP
by 33.4% and oxLDL by 5.9% (P=0.01). Surprisingly, even ‘‘control’’ product A reduced systolic BP (27.89 mmHg; 95%CI:
211.45 to 24.3) and diastolic BP (25.54 mmHg; 95%CI: 27.79 to 23.29). The BP reductions were similar with the other 3
products. Limitations of the study are that the trial period was relatively short and that a better ‘‘BP control’’ product would
have been preferable.
Conclusion: The creams (particularly the LMN) have anti-inflammatory and antioxidant effects in addition to lowering LDL-c,
Apo B and ApoB/ApoA ratio. Thus, the soluble fiber effects amplified with sterols (as contained in the cocoa creams) provide
new dietary therapeutic perspectives.
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Dietary factors influence plasma lipid levels (such as low-density
lipoprotein cholesterol; LDL-c), blood pressure (BP), or other
cardiovascular disease (CVD) biomarkers [1–4]. Modifications of
nutritional components, consumption of specific foods, food
additives and supplements are the major dietary approaches to
reducing the risk-factors. The most beneficial CVD changes result
from: reducing intake of saturated (SFA) and trans fats; an
adequate intake of polyunsaturated (PUFA) and increasing the
amount of monounsaturated fats (MUFA); fortifying foods with
plant stanols or sterols; adding nuts to the diet; increasing the
intake of soluble fiber and soy protein; increasing the consumption
of oily or fish-derived omega-3 fatty acid or cocoa products and
flavonols [5,6]. However, the effects of incorporating some of these
ingredients into a commercial product for consumption as a
dietary component are unknown.
In the present study, the hypothesis is that new cocoa product
formulations with low saturated fatty acids, moderate sugar
content, plus hazelnuts, or phytosterols or soluble fiber in an
appetizing cream mixture can induce a reduction of CVD
biomarkers when consumed as a dietary supplement.
The aim of our study was to assess the effects of cocoa or
cocoa+hazelnut, or cocoa+hazelnuts+phytosterols, or cocoa+ha-
zelnuts+phytosterols+soluble fiber on intermediate metabolic
markers of CVD risk. The formulation was tested as part of a
calorie-balanced weight-maintaining diet in prehypertensive and
stage-1 hypertensive and hypercholesterolemic volunteers.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participants
The participants were community-dwelling men and women
.20 years of age, with prehypertension (systolic BP: 120–
139 mm Hg or diastolic BP: 80–89 mm Hg) and stage 1
hypertension (systolic BP: 140–159 mm Hg or diastolic BP: 90–
99 mm Hg), LDL-c between 3.35 mmol/L (130 mg/dL) and
4.88 mmol/L (189 mg/dL), and at least one CVD risk factor such
as age (men $45 years; women $55 years), smoking habit, low
high density lipoprotein cholesterol (HDL-c) concentration of
,1.0 mmol/L (40 mg/dL) and ,1.18 mmol/L (46 mg/dL) in
men and women, respectively; family history of premature CVD
(in male first-degree relative ,55 years of age, in female first-
degree relative ,65 years of age. Exclusion criteria included
diabetes mellitus, any chronic disease, current hypolipemic
treatment, triglycerides (TG) .3.97 mmol/L (350 mg/dL) in
fasting state, body mass index (BMI) .35 kg/m
2.
Ethics
Participants provided written informed consent prior to
enrolment into the trial and eligibility or exclusion was assessed
by the attending physician based on a review of the clinical
records, followed by a screening visit. The study was approved by
the Clinical Research Ethical Committee (also known as an
Institutional Review Board) of the Hospital Universitari Sant Joan de
Reus and at 3 Primary-Care Centers (Alcover, Vic, Centelles)
where participants were recruited and the human experimentation
was conducted.The study protocol was in accordance with the
Declaration of Helsinki and good clinical practice guidelines.
Interventions
Diet design. The study was a controlled, double-blind,
parallel, multi-centered study in which the 4 different cocoa
cream products were introduced into a calorie-balanced diet for 4
weeks. There was a prior stabilization period of 2 weeks in which
all participants received the cocoa cream product (designated
control product A) in order to assess the subject’s tolerance to the
product. In the stabilization period of 2 weeks duration, the
isocaloric intake was the Spanish composition diet [7]; 39% of
total energy as fat and, of which, 13% as SFA. In the intervention
period of 4 weeks duration, the isocaloric diet prescribed was 35%
of total energy as fat of which ,7% was SFA, 50% of total energy
as carbohydrate, 15% of total energy as protein and ,200 mg/d
of cholesterol [8,9].
The nutritional composition of the cocoa cream was taken into
account as a basic food component of the diet. The inclusion of
cocoa products resulted in a reduction of olive oil as the
predominant fat. Also, to reduce SFA intake, items such as
sausages, cured or mature cheese, whole fat milk and whole fat
yogurt were avoided. However, dietary energy recompense was by
increasing intake of carbohydrates provided by bread, pasta and
potatoes. Further, we recommended the avoidance of chocolate,
products containing stanol esters or sterols, food items or products
rich in fiber or omega-3, nuts and soya or soya products.
Consumption of legumes was limited to a maximum of 3 times per
week.Three-day food records at the beginning and end of the
intervention period and a 24 h dietary recall at 2 weeks within the
intervention period were used to assess adherence to the
recommended diet. The nutritionists underwent training to ensure
standardization of procedures and dietary evaluations. The
nutrient composition of the diet was calculated using the Re ´pertoire
Ge ´neral Des Aliments [10].
The trial was conducted in one clinical centre (Hospital
Universitari Sant Joan de Reus) and 3 Primary-Care Centers (Alcover,
Vic, Centelles).
Cocoa cream products
A low saturated fat, calorie-balanced diet included 6 units
(13 g/unit, 465 Kcal/d) of product A: cocoa; or product B:
cocoa+hazelnut (30 g/d hazelnuts; 5 g hazelnut in each unit); or
product C: cocoa+hazelnuts+phytosterols (2 g/d); or product D:
cocoa+hazelnuts+phytosterols+soluble fiber (20 g/d). This last
product was designated LMN (patent WO2007063158A2). The
quantities of nuts (30 g/d) and soluble fiber (20 g/d) were chosen
since these are amounts that have shown anti-CVD effects [5,6–
8,9].
All the products contained approximately 1 g of cocoa solids per
unit. All the different cocoa cream products were formulated,
manufactured and nutrient evaluated using USDA food compo-
sition tables. Individual doses were consumed as snacks or as
additions at mealtimes, but without milk or other dairy products.
Compliance was monitored by empty wrapper counting and
any non-consumed doses were collected at follow-up clinical visits.
We defined non-compliance as a cream consumption of ,80%.
Adverse effects were coded according to the MedDra dictionary
(version 8.0) and categorized by body system and preferred term.
Outcomes
Primary outcome measures were BP, LDL-c, apolipoprotein B-
100 (Apo B), ApoB/ApoA ratio, oxidized LDL (oxLDL) and high-
sensitive C-reactive protein (hsCRP). The variables were deter-
mined at baseline (after 2 weeks of stabilization period) and
following ingestion of one or other of the 4 different cocoa cream
products introduced into a calorie-balanced diet for 4 weeks.
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BP was measured 3 times at 1-minute intervals using an automatic
sphygmomanometer (OMRON HEM-907; Peroxfarma, Barce-
lona, Spain) and the mean value recorded. Weight and height
were measured with the participants in indoor clothing without
shoes, using calibrated scales and well-mounted stadiometer (An ˜o ´
Sayol S.A., Huelva, Spain). Bodyweight was measured every 2
weeks and, if the weight varied by .1 Kg, the caloric intake was
modified to maintain basal bodyweight for the rest of the study.
Waist circumference (WC) was measured midway between the
lowest rib and the iliac crest using an anthropometric tape.
In a subgroup of participants, endothelial function was
measured using fingertip Peripheral Arterial Tonometry (Endo-
PAT) equipment (Hamar Medical, Caesarea, Israel). The Endo-
PAT index was calculated as the ratio of the digital pulse volume
during reactive hyperemia4the value at baseline. A value of ,1.6
Arbitrary Units (AU) was indicative of endothelial dysfunction.
Biomarkers
Blood was drawn from each patient following an overnight fast.
To reduce intra-individual day-to-day variability, the blood
sampling was performed on two separate days at the end of the
stabilization period (recorded as ‘‘baseline’’) and at the end of the
intervention period. The blood samples were stored at 280uCi n
the central laboratory’s Biobanc (bancmb@grupsagessa.com) until
required for batched analyses.
Lipids and other biomarkers were measured centrally at Hospital
Universitari Sant Joan de Reus (Catalonia, Spain) or in the URLA
laboratories of the Facultat de Medicina de Reus.
Total cholesterol (TC), TG, HDL-c, apolipoprotein (Apo) A-1
and Apo B-100, high-sensitive C-reactive protein (hsCRP),
interleukin-6 (IL-6) in serum were performed using standard
methods in an autoanalyzer (Beckman Coulter-Synchron, Galway,
Ireland). LDL-c was calculated by means of the Friedewald
formula [11].
Oxidized LDL (OxLDL) by immunoassay (Mercodia AB,
Uppsala, Sweden) was measured in EDTA plasma. Vascular cell
adhesion molecule type 1 (VCAM-1), intercellular adhesion
molecule type 1 (ICAM-1) (R&D Systems, Minneapolis, USA)
were measured in citrate plasma using ELISA kits.
Sample size calculation
This trial was an exploratory study designed to assess the
beneficial effects on several CVD biomarkers of cocoa cream
additions to the diet. With 25 valid subjects per group, our study
was sufficiently powered (i.e. 80%) to detect relevant magnitude of
differences such as those observed in a recent meta-analysis [12]
for systolic BP of 4.5 mmHg (SD: 10–13 mm Hg) and for diastolic
BP of 2.5 mm Hg (SD: 7–9 mm Hg), and a two-sided alpha of
5%. However, we planned to include two additional patients per
arm to guarantee an 80% power to detect, as well, a difference of
at least 13 mg/dL (0.34 mmol/L) in LDL with a SD of 17 mg/dL
(0.44 mmol/L) [13] and a two-sided alpha of 5%. Thus, at least 27
subjects in each arm were recruited.
Further, with 27 valid subjects per group, the study has 80%
power to detect a difference of at least 0.34 mmol/L (13 mg/dL)
in LDL-c with a SD of 0.44 mmol/L (17 mg/dL), with a two-
sided alpha of 5%.
Randomization sequence generation and
implementation
The randomization code was computer-generated random
number sequence in gender-stratified blocks of 4 persons each.
Center and treatment assignment codes were allocated via an
interactive electronic response system administered by the
Barcelona Randomization Unit, which took no further part in
the study.
Blinding
The cocoa cream products were manufactured by La Morella
Nuts S.A. (Castellvell, Spain) specifically for the trial (Table 1) and
all the products were designed to have the same texture and visual
characteristics.
The participants, clinical investigators and laboratory personnel
were blinded with respect to the type of cream being consumed.
Statistical analysis
Results are expressed as mean 6 SD, baseline-adjusted least
square means (95% confidence intervals; 95%CI), median (inter-
quartile range; 25
th percentile, 75
th percentile) or frequencies and
percentages (%).
We analyzed all continuous variables that had Gaussian
distributions using standard ANCOVA (or mixed models when
the endpoints were measured repeatedly over time) with the
(co)variance type set to unstructured [14], including the baseline
observation as a covariate in both cases. For the rest of continuous,
but non-Gausian variables, we used the same model with a prior
rank transformation of the dependent variable [15]. The same
model was applied for ICAM and VCAM for additional and
suportive analyses after a prior log10 transformation of the data.
For measures other than the anthropometric and clinical variables,
the comparisons versus control were all included in the tables, with
further pair-wise comparisons included. Only comparisons versus
control were conducted for the rest of variables. Fisher’s protected
Table 1. Nutritional composition of each cream (13 g dose).
a
Content per dose
Product
A
Product
B
Product
C
Product
LMN
Energy, Kcal 77 77 73 73
Carbohydrate, g 6.6 5.6 5.4 4.5
Protein, g 0.2 0.9 0.8 0.9
Total fat, g 6.0 6.1 5.8 6.1
Saturated fat, g 1.2 1.3 1.2 1.4
Stearic fatty acid, g 0.3 0.6 0.6 0.5
Monounsaturated, g 3.0 3.6 3.0 3.4
Polyunsaturated, g 1.4 0.9 1.3 1.0
n-6, g 3.0 1.3 1.3 1.0
Fiber, g 0.3 0.7 0.7 2.7
Vitamin E, mg 2.0 1.3 1.3 1.3
SFA/USFA 1:3.5 1:3.32 1:3.44 1:3.22
MUFA/PUFA 1:2.06 1:0.42 1:0.46 1:0.40
SFA/MUFA 1:1.14 1:2.33 1:2.35 1:2.48
SFA/PUFA 1:2.35 1:0.98 1:1.09 1:0.73
Abbreviations: Kcal: kilocalories; g: gram; n-6: omega 6 (linoleic acid); SFA:
saturated fatty acids; USFA: unsaturated fatty acids; MUFA: monounsaturated
fatty acids; PUFA: polyunsaturated fatty acids; Product A: cocoa cream; Product
B: cocoa+hazelnut cream; Product C: cocoa+hazelnut+phytosterols cream;
Product D (for the purpose of the present study termed LMN product):
cocoa+hazelnut+phytosterols+soluble fiber cream.
a Nutrient composition calculated from data provided by the manufacturers
and with USDA food composition tables.
doi:10.1371/journal.pone.0031103.t001
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for type I error and. As such, pair-wise treatment inferential
comparisons were applied only if this factor was significant.
The main analyses were performed with the intent-to-treat
(ITT) population i.e. subjects with at least one post-baseline
measurement. A secondary analysis was applied to a per-protocol
(PP) subset of patients who were free of any major violations of the
protocol. The analyses shown in the text and tables were
performed on the ITT population. The sensitivity analyses
performed on the PP population gave very similar results.
The level of significance was set at the standard two-sided level
of 5%. All analyses were performed using SAS (version 9.1.3)
software (SAS Institute Inc., Cary, NC, USA).
Results
Participant flow
Figure 1 describes the flow of participants through the study.
Recruitment
The participants were recruited between April 2005 and
December 2005.
Baseline data; Characteristics of participants
The groups receiving the 4 different cocoa cream products
appeared to have some differences at baseline; group A had the
youngest individuals while group B contained fewer individuals
with high BP and family history of premature CVD. No significant
differences were observed in the other baseline characteristics
(Table 2).
Numbers analyzed
There were 283 individuals who were considered eligible for the
study (Figure 1). The 113 remaining participants were randomized
in ITT analysis; 46 men and 67 women having completed the
study. Finally, 11 participants were excluded from the PP analysis.
Outcomes and estimation
The results (anthropometric measures, lipid profile, CVD
biomarkers and dietary adherence) at 4 weeks of the intervention
period are summarized in Tables S1, S2, S3 and S4.
The differences observed with respect to dietary fiber intake can
be explained by the fiber content in the LMN product.
Figure 1. Flow diagram of participants. From the ITT population (n=113), 11 participants were excluded because of lack of compliance with
product consumption (i.e. ,80% product consumption). Hence, the PP population was 102. Product A: cocoa-only cream; Product B: cocoa+hazelnut
cream; Product C: cocoa+hazelnut+phytosterols cream; Product D (for the purpose of the present study termed LMN product):
cocoa+hazelnut+phytosterols+soluble fiber cream; ITT: intention to treat; PP: per protocol.
doi:10.1371/journal.pone.0031103.g001
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primary end-points in males and females.
Compliance was high: 94% with the 4 different cocoa cream
products and 98% with the diet.
During the intervention period, the 4 groups consumed
approximately 10% of energy as SFA (Table S4). Compared with
the control group, inclusion of hazelnuts induced higher MUFA
and lower PUFA content, while the product LMN group had a
higher intake of dietary fiber (P,0.0001) (Table S4).
Anthropometric and clinical measurements
No changes in bodyweight and WC measurements were
observed at the end of the intervention period (Table S1).
Surprisingly, 4 weeks on product A (designated as control) reduced
systolic BP (27.89 mmHg; 95%CI: 211.45 to 24.3) and diastolic
BP (25.54 mmHg; 95%CI: 27.79 to 23.29).
These intra-group changes for group A were greater than that
observed in the other 3 treatment groups. The between-group
comparisons showed no statistically significant differences vs.
control in systolic BP, and only group B was significantly different
from control with respect to diastolic BP (P=0.0357).
The treatment effect was not heterogeneous between individuals
who were pre-hypertensive and those at stage-1 hypertension.
Lipid profile. Compared to the control group, after 4 weeks
product C reduced LDL-c by 211.2% (0.47 mmol/L; 95%CI:
0.23 to 0.71; P=0.0002), and Apo B/Apo A ratio by 27.8%
(0.054; 95%I: 0.014 to 0.094; P=0.0085). LMN cream decreased
LDL-c by 9.2% (0.39 mmol/L; 95%CI: 0.15 to 0.64; P=0.0018)
and Apo B/Apo A ratio by 210.5% (0.074; 95%CI: 0.033 to
0.115; P=0.0005) (Table S2).
CVD biomarkers. Compared with control group, LMN
reduced hsCRP by 0.96 mg/L (95%CI: 0.02 to 2.04; P,0.0083)
and oxLDL by 4.0 U/L (95%CI: 0.51 to 7.51; P=0.0252) (Table
S3).
Ancillary analyses
Endo-PAT subgroup. A subgroup of participants (n=14)
from within the control product group A were tested for
endothelial function pre - and 2-week post-intervention using the
Endo-PAT system. We observed that the consumption of cocoa
improved the vasodilator response (as measured by fingertip
tonometry) from 1.800 to 2.173 AU, pre- versus post-intervention
(mean 0.373 AU; 95%CI: 20.044 to 0.702; P=0.029).
Adverse events
All participants consumed the cocoa cream during the
stabilization period and none reported any adverse effects. During
the intervention period, two participants reported a bloating
feeling and one reported poor appetite.
Discussion
Interpretation
Cocoa cream containing other palatable ingredients such as
those of the ‘‘portfolio’’ diet (in the current study termed the LMN
product) beneficially modulates the CVD biomarkers measured
[16–18].
Compared to control cocoa cream, the reductions in plasma
LDL-c observed with cocoa+hazelnuts+phytosterols of 211.2%
and with LMN of 29.2% are of similar magnitude to that of
sterols and stanols (2 g/d) or of Plantago ovata husk (14 g/d) [19].
Of note is that the phytosterols+soluble fiber combination had a
similar lowering effect on plasma LDL-c. However, contrary to
expectation, the hypocholesterolemic effect was neither additive
nor synergistic. Further, the cocoa+hazelnuts+phytosterols cream
reduced the ApoB/ApoA ratio by about 211.8% and LMN
reduced the ratio by 210.5% due, mainly, to a moderate
reduction in plasma Apo B-100. Since Apo B is considered the
better indicator of CVD risk than the conventional LDL-c status
[20,21], the reduction of the ApoB/ApoA ratio to values ,0.7
becomes a therapeutic target [20–23].
Compared to the control cream, LMN reduced oxLDL by
26%. In this case, the addition of soluble fiber reduced oxLDL
plasma concentrations by about 25.9%; a similar LDL antioxi-
dant reduction observed with the consumption of 14 g/d for 8
weeks of the soluble fiber Plantago ovata husk [19]. As such, soluble
fiber addition can exert a greater LDL antioxidant effect than
cocoa alone [24,25].
Compared with control cocoa cream product, LMN reduced
hsCRP by 233.4%, which indicates an anti-inflammatory effect of
this product. Soluble fiber is the additional ingredient in the LMN
product which may be responsible for this lowering of hsCRP; an
Table 2. Baseline characteristics of study participants.
Product A (n=28) Product B (n=28) Product C (n=30) Product LMN (n=27) Total (n=113)
Age, years 49.7969.53 56.79610.46 56.03610.06 53.3368.42 54.0369.93
BMI, Kg/m
2 28.3163.25 27.3063.01 28.5363.22 28.2863.56 28.1263.25
Gender, male 11 (39.3%) 12 (42.9%) 13 (43.3%) 10 (37.0%) 46 (40.7%)
CVD risk factor:
Age 16 (57.1%) 23 (82.1%) 22 (73.3%) 20 (74.1%) 81 (71.7%)
Smoker 8 (28.6%) 8 (28.6%) 7 (23.3%) 5 (18.5%) 28 (24.8%)
High BP 12 (42.9%) 8 (28.6%) 13 (43.3%) 11 (40.7%) 44 (38.9%)
HDL-c* 0 (0.0%) 1 (3.6%) 2 (6.7%) 4 (14.8%) 7 (6.2%)
F-HD
+ 6 (21.4%) 2 (7.1%) 3 (10.0%) 4 (14.8%) 15 (13.3%)
ITT population.
Results are expressed as means 6 SD or frequencies (%).
Abbreviations: Product A: cocoa cream; Product B: cocoa+hazelnut cream; Product C: cocoa+hazelnut+phytosterols cream; Product D (for the purpose of the present
study termed LMN): cocoa+hazelnut+phytosterols+soluble fiber cream; BMI: body mass index calculated as weight in kilograms divided by height in meters squared;
CVD: cardiovascular disease; HDL-c: high density lipoprotein cholesterol, * ,1.0 mmol/L (40 mg/dL) and ,1.18 mmol/L (46 mg/dL) for men and women, respectively; F-
HD: family history of premature heart disease, +in male ,55 years, in female ,65 years in first-degree relative.
doi:10.1371/journal.pone.0031103.t002
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the portfolio diet [26] and the anti-inflammatory effect of cocoa
polyphenols [27].
The large blood pressure lowering effect (systolic BP by
27.8 mm Hg and diastolic BP by 25.4 mm Hg) of the cocoa
product warrants further investigation. Further studies on product
A composition are underway to seek an explanation for the
clinically significant reduction in BP we observed. Because of these
reductions induced by the ‘‘control’’ product, no further statistical
comparison versus the other manufactured products were made
with respect to BP.
While the 4 cream products contained the same amount of
cocoa and polyphenols i.e. about 1 g/unit together with 10 mg/
unit of phenolic compounds and 10% of SFA, the addition of
hazelnuts (30 g/) in the 3 other cream products changed the
MUFA contribution to 24% and PUFA to about 10%. This
produces a dietary composition of 20% MUFA, 5% PUFA and
10% SFA; a composition that is recommended by scientific
societies [7,8]. The sugar content of the 4 creams accounts for
#50% of total energy. In the present study, participants
maintained their weight and WC throughout the intervention
period, reinforcing the benefits of the cocoa intake traded-off
against sugar, fat and calorie count [28]. In a subgroup of
participants consuming the cocoa cream product A, an arterial
vasodilatory effect was observed, as measured by Endo-PAT which
provides a quantitative evaluation of endothelial dysfunction [29].
Recently, the digital Endo-PAT device was reported not only to
predict patients with ischemic heart disease [29] but also an
improvement in endothelial function as a consequence of cocoa
product consumption [30]. The arterial vasodilatory effect of
cocoa cream observed in present study could explain, at least in
part, the reduction in BP.
Generalizability
The present exploratory study showed that cocoa extracts,
mixed with other food ingredients (such as those in the ‘‘portfolio
diet’’) to produce a palatable cream product is a new alternative to
improve CVD biomarkers, despite the consumption being over a
very short time in the present trial. These CVD beneficial effects
need to be demonstrated over a longer-term of consumption, and
with doses which can be incorporated within a diet recommend-
able for CVD risk reduction.
Limitations
The study period with cocoa cream products focused on short-
term surrogate markers of inflammation, as opposed to clinically
relevant outcomes in the patients. The optimum daily intake of the
products to maximize the benefit remains to be determined. An
appropriate control product is needed since even the cocoa cream
alone (product A), although effective as control for LDL-c plasma
level outcomes, had a BP lowering effect.
Overall evidence
We conclude that palatable cocoa cream products, particularly
the LMN cream, have anti-inflammatory and antioxidant effects
in addition to a beneficial lowering effect on LDL-c, Apo B and
ApoB/ApoA ratio. Thus, the effect of soluble fiber amplified with
sterols (as contained in the cocoa creams) provides new dietary
therapeutic perspectives in addressing cardiovascular disease.
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